RESEARCH

Personalized Tumor Growth Prediction with Multiscale Tumor Modeling

Serbulent Unsal^{1,3}, Aybar Acar^{2,3}, Mehmet Itik¹, Ayse Kabatas¹, Oznur Gedikli¹, Feyyaz Ozdemir¹ and Kemal Turhan^{1*}

*Correspondence:

kturhan.tr@gmail.com

¹Karadeniz Technical University, Universite Mah., Trabzon, Turkey

²Cancer Systems Biology Laboratory (KanSiL), Middle East Technical University, Dumlupinar Bulvarı, No:1, 06800 Ankara, Turkey

Full list of author information is available at the end of the article

Abstract

Background: Cancer is one of the most complex phenomena in biology and medicine. Extensive attempts have been made to work around this complexity. In this study, we try to take a selective approach; not modeling each particular facet in detail but rather only the pertinent and essential parts of the tumor system are simulated and followed by optimization, revealing specific traits. This leads us to a pellucid personalized model which is noteworthy as it closely approximates existing experimental results.

Method: For years, research has focused on modeling tumor growth but not many studies have put forward a framework for the personalization of models. In the present study, a hybrid modeling approach which consists of cellular automata for discrete cell state representation and diffusion equations to calculate distribution of relevant substances in the tumor micro-environment is favored. Moreover, naive Bayesian decision making with weighted stochastic equations and a Bayesian network to model the temporal order of mutations is presented. The model is personalized according to the evidence using Markov Chain Monte Carlo. Ultimately, this way of thinking about tumor modeling leads us to a vascular multi-scale model of tumor growth.

Results: To validate the tumor model, a data set belonging to the A549 cell line is used. The data represents the growth of a tumor for 30 days. We optimize the coefficients of the stochastic decision making equations using first half of the timeline. Then we predict next 15 days of growth without any other supervision. Results are promising with their low error margin and simulated growth data is in line with laboratory results.

Conclusion: There are many subsystems which have an effect in the growth of a tumor. A detailed model which includes all of them is currently virtually impossible to implement. We have therefore focused on a system that only includes fundamental components in this study, and have evaluated its predictions. We propose novel probability functions to obtain a personalized model and estimate the individual importance (weights) of each with parameter optimization. Our approach of using simulated annealing for parameter estimation and the subsequent validation of the prediction with in-vitro tumor growth data are, to our knowledge, unique in the literature.

Keywords: cancer; tumor modeling; personalized tumor growth

1 Background

Despite much progress in oncology, molecular biology, and related fields, cancer is still a condition for which the prognosis is generally a shortened lifespan or lowered quality of life, frequently dramatically so. The complex and individually particular

behavior of cancer decreases success rates of cancer therapies. The usual steps of cancer therapy are: deciding on tumor's pathological type, staging the cancer using clinical data and planning the therapy according to medical guidelines which are informed by bulk statistics. In this routine, there is little room to calculate and predict patient's therapy response in a bespoke way.

Mathematical models that use patient specific data and up-to-date scientific evidence has implications for the evidence based practice of personalized medicine. Use of individually tuned mathematical models give clinicians the ability to compare alternative therapy plans and predict outcomes. These models have an important role in the early drug development and for development of therapy scheduling. However, this search for personalized therapy has not yet met success. In the present study we propose a hybrid tumor model for the Non-Small Cell Lung Cancer (NSCLC) and a personalization framework.

Different approaches exist to develop tumor models. Continuous tumor models simulate tumor growth with in a set of differential equations, making them good options in modeling complex systems [1–6]. Simulating attributes of a tumor at tissue scale is trivial with continuous models. However, it is a non-trivial challenge to use them for simulating individual cell dynamics or discrete events in a cell or in the cell's microenvironment. Discrete models are a solution to this problem. Simulation of the tumor system dynamics, which cannot be easily modeled by the continuous approach can be possible with the discrete modeling techniques such as the orientation mechanism of tumor according to nutrients [7], effects of the cell adhesion on tumor growth as well as effects of the proteolytic enzymes [8], competition between cell colonies [9], genetic parameters on the tumor movement [10]. Hence, it could be concluded that, discrete models provide sufficient flexibility in modeling cell-state scale tumor dynamics. Continuous and discrete modeling approaches could be thus combined into hybrid models [11]. Most of the time a discrete model is created at cell scale to simulate behavior of the cells and a continuous model is used at tissue scale to simulate distribution of substances like oxygen or glucose in tumor micro environment in hybrid modeling [9, 12].

In this study, such a framework has been developed for personalized tumor modeling that includes tumor and tissue specific parameters gathered from the literature for A549[13], which is a well known cell line derived of lung adenocarcinoma. Cellular automata are used for discrete cell state representation. Substance distribution in the vascular tumor micro-environment is calculated by using partial differential equations. Mutations of cells are modeled with a probabilistic network. A Naive Bayes approach is chosen for the decision making module of each cell. Weighted stochastic equations are created for modeling decisions of the tumor cells. Overall, this approach enables us to create a model which can easily be personalized by the optimization of individual parameters using simulated annealing. Results are promising with their low error margin and the simulated growth data fits well to xenograft model.

State of The Art

According to the best of our knowledge;

- Our model is the first such model able to accurately regress the personalized growth of lung adenocarcinoma given data from the stages.

- Our approach of personalization uses simulated annealing and its validation with a xenograft model is novel.
- The model also incorporates a hierarchical Bayesian network of the tumor which is created from A549 mutation data and uses this model to predict the order of occurrence and timing of consecutive mutations during tumor progression. Although there are a few models which use mutation data, our model uses temporal and hierarchal order of specific cancer driver genes which has, thus far, to our knowledge, has not been leveraged..
- We propose novel probability functions to obtain a personalized model and estimate the importance (weight) of each with optimization.

2 Results

2.1 Consistency

A tumor model should be consistent with the basics of tumor biology. We first test this consistency using experimental data. Studies show that tumor growth accelerates under hypoxia [14–17]. Figure 1 shows our model is consistent with literature for hypoxic growth dynamics. Pearson correlation coefficient calculated between model and study for hypoxic and normoxic conditions. A strong correlation for both hypoxic ($r=0.992$) and normoxic ($r=0.991$) conditions is observed on tumor volume. Also as seen in Figure 2 in hypoxia which could be defined as 10% O_2 of normoxia [18] apoptotic region is considerably larger and tumor shows migrative behavior which is also in line with experimental results [19, 20]. In the figure,

Many studies have shown that glucose is an important factor in tumor growth. This fact was shown not only *in-vitro* [21–24]; but also *in-vivo* experiments [25]. Our model is in line with these studies as shown in Figure 3. Pearson correlation coefficient calculated between model and study for normal and low glucose conditions. A strong correlation for both normal ($r=0.998$) and low glucose ($r=0.898$) conditions is observed on tumor cell number. Limitation of growth under low glucose can also be observed by comparing tumor morphology as seen in Figure 4.

Chemotaxis is a fundamental mechanism that determines tumor morphology: defined as motility of cells towards resources like oxygen and glucose. To ensure that cells in our model simulate chemotactic behavior we created a set of capillaries as shown in Figure 5. Subsequently, the growth of the simulated tumor was monitored. It was observed that, in simulation, the tumor cells tended to the capillaries as shown Figure 6 which is in line with *in-vitro* and *in-vivo* studies [26–29].

Tumor growth patterns fit a Gompertz curve, which is a sigmoid function [30–35]. Our simulations are also validated by the observation that the tumor growth process can be defined as a sigmoid curve that starts with a high exponential growth

rate but eventually levels-off with saturation (see Figure 7). Pearson correlation coefficient calculated between model and study for long term tumor growth. A strong correlation ($r=0.8$) for long term tumor growth is observed between tumor cell number and maximum diameter of tumor.

Data from Figure 1 Figure 3 and Figure 7 were extracted using Web Plot Digitizer [36] and used in calculation of the Pearson correlation coefficients.

Mutations are the foundation for the genetic structure of tumors and these are also what determined the individual differences in different cancers. In the past,

some of mathematical tumor models have used this fact. Some models incorporate the effects of mutation on only one locus [38–40] while some have grouped several gene mutations according to their phenotypes [41–43]. Yet, according to the best of our knowledge, none of them inspect the effects of multiple cancer driver genes and their temporal order together, in a multiscale model. We use the results of a temporally ordered inference model generated from a multi-patient study [44]. For example, in the model, occurrence of KRAS mutation is a prerequisite for TP53 mutations and TP53 mutation is a prerequisite for the occurrence of CDK2NA mutations. In our simulations, as well, we have observed that TP53 mutations only occur after KRAS mutations and only in the cells which already have accumulated KRAS mutations. Likewise, we were able to recreate other dependencies, e.g TP53 to CDK2NA. Figure 8 shows how mutations occur in a temporal and hierarchical order, indicating that our modeling strategy is successful in simulating the actual mutation timelines in tumor progression. Using this system, a multi-clonal tumor model is created, allowing for the fact that different parts of a tumor may have different progressions of mutation.

2.2 Personalization: Estimating Parameters per Individual

Different approaches are found in the literature for the personalization of mathematical tumor models. For example, Prokopiou *et. al.* calculate the proliferation saturation index by using ratio of tumor volume to the carrying capacity of tumors [45]. On the other hand, Saribudak *et. al.* use gene expression values to personalize their model [46], and Kogan used PSA levels to individualize their model [47].

In our model, we used a stochastic decision approach in cellular automata. The decisions of each cell simulating automaton are based on the tumor microenvironment, e.g. oxygen and glucose concentrations. Weights of these variables in terms of their effect on a particular individual's tumor are determined by using optimization. We use simulated annealing as the optimization method.

The parameter ptimization results can be seen in Figure 9. Results were obtained by optimizing parameters using the first 15 days of tumor growth data gathered from the experimental results from a xenograft [48]. Afterwards, the simulation was run with the optimized parameters. Predicted tumor growth after optimization is also shown Figure 9. The model's prediction closely mirrors the growth trend of the xenograft.

Materials and Methods

Details of the Tumor Model

We utilize the model proposed by Gerlee and Anderson [49] as a basis to our model. The Figure 10 shows the components an comprehensive tumor model should have. model.

Our model is specific to lung cancer adenocarcinoma. The fixed parameters used in the model are gathered from in-vitro and in-vivo experiments from literature. The modules implemented in this study are shown in Figure 11.

Cellular automata are used to make decisions based on substance distribution and mutation effects, since rule based automata are well suited to simulating a system which depends on many variables. Decisions for migration, proliferation, apoptosis and substance consumption, are based on the state of each cellular automaton, which use a stochastic decision making process.

Each module will be discussed in the subsequent sections. In terms of the software infrastructure; Python [50] is used as the main platform for implementation of model, FiPy [51] is used to solve PDEs and Cython [52] for increased efficiency of simulation. Finally, PyGame [53] was used for implementing the graphical user interface and for visualization.

3 Model Parameters

Most of the physical parameters used in our simulator are specific to lung cancer adenocarcinoma, while some are general parameters for tumors or tumor microenvironments. The A549 cell line was selected as a basis, since it represents a very common lung tumor presentation. Table 1, below, shows the parameters, symbols, and values used, with references.

Table 1 Parameters Used In Model

Parameter	Symbol	Value	Specific to A549
Tumor Cell Doubling Time	δ_t	22 h [54]	Yes
Oxygen Background Concentration	c_o	$4.375 \times 10^{-1} \text{ mM}$ (calculated from [55])	Yes
Oxygen Diffusion Constant	d_o	$8.0 \times 10^{-9} \text{ m}^2 \text{ sec}^{-1}$ [56]	No
Oxygen Uptake Rate	u_o	$0.91 \times 10^{-15} \text{ mol min}^{-1}$ [55]	Yes
Hypoxia Induced Apoptosis Threshold	h_{oa}	$0.015 \times c_o$ [57]	Yes
Hypoxia Induced Glycolysis Threshold (Upper Limit)	h_{gu}	$0.05 \times c_o$ [57]	Yes
Hypoxia Induced Glycolysis Threshold (Lower Limit)	h_{gl}	$0.01 \times c_o$ [57]	Yes
Hypoxia Induced Apoptosis Rate	h_{ar}	%55 [57]	Yes
Oxygen Threshold Proliferative to Quiescence	o_{pq}	1 mmHg [58]	No
Glucose Background Concentration	c_g	17 mM [56]	No
Glucose Diffusion Constant	d_g	$1.35 \pm 0.13 \times 10^{-5} \text{ cm}^2 \text{ sec}^{-1}$ [59]	Yes
Glucose Aerobic Uptake Rate	u_{ga}	$4.1 \times 10^{-11} \text{ mol cell}^{-1} \text{ sec}^{-1}$ [60]	Yes
Glucose Anaerobic Uptake Rate	u_{gan}	$6 \times 4.1 \times 10^{-11} \text{ mol cell}^{-1} \text{ sec}^{-1}$ (Calculated from [60])	Yes
Hypoglycemia Induced Apoptosis Threshold	h_{ga}	8 mM [61]	No
Glucose Threshold Proliferative To Quiescence	g_{pq}	12 mM [61]	No
Hydrogen Ion Diffusion Constant	d_h	$1.4 \times 10^{-6} \text{ cm}^2 \text{ sec}^{-1}$ [62]	No
Hydrogen Ion Production Rate	p_h	$1.5 \times 10^{-18} \text{ mol cell}^{-1} \text{ sec}^{-1}$ [49]	No
Background pH level	c_{ph}	7.35 [63]	Measured in Lung Tissue
H+ Background Concentration	c_p	$1.11 \times 10^{-13} \text{ mol cm}^2$ (Calculated from [63])	Measured in Lung Tissue
pH Induced Apoptosis Threshold	p_{ha}	5.5 [64]	No
Optimal pH for Tumor	p_{ho}	6.8 [65]	No

4 Diffusion of Substances in the Tumor Microenvironment

Tumor growth consists of the *consumption*, *growth*, *production*, *migration*, *apoptosis* and *necrosis* phases. Tumors need oxygen and glucose to grow and they also produce waste. If a tumor can't find enough oxygen it goes into hypoxia. If the tumor can't find enough nutrition (glucose), hypoglycemia starts. Producing waste (H^+ ions) is another function of cell metabolism but also helps tumor to create an advantageous microenvironment for itself, as low pH is favored by most tumors, giving them a competitive edge over normal cells.

Substance diffusion into the tissue is modeled as:

$$\frac{\partial m}{\partial t} = D \nabla^2 m + m H s_{cap} - s_{cell} \quad (1)$$

Equation 1 calculates the substance diffusion within the tissue boundaries. We assume that there are capillaries spread in tissue which supply fixed substance flow to the tissue and tumor cells which consume said substance. This equation is valid for consumed substances such as oxygen and glucose in our model. Waste substances such as H^+ ions produced by tumor cells (and normal cells, alike) are,

likewise, removed by capillaries. Accordingly, for waste, we modify our diffusion model as shown below to simulate this phenomenon:

$$\frac{\partial m}{\partial t} = D \nabla^2 m - mHs_{cap} + s_{cell} \quad (2)$$

In equations 1,2 s_{cell} stands for consumption or production of substance by tumor cells and s_{cap} is the fixed term for the substance delivery or removal capacity of capillaries. Finally, H is a very large number which is used to remove effects of neighbors for the specific coordinate where the capillary exits. The particulars are elaborated on in Appendix A.

Once, the conditions of tumors' microenvironments are thus modeled, internal dynamics of tumor cells can be explored.

5 Intracellular Model

Throughout their lifecycles, cells make several critical biochemical decisions. The first among these is about proliferation. Tumor cells decide whether they will proliferate, or not, based on genetic and microenvironment conditions. Another critical decision is to trigger apoptosis, if necessary. Furthermore, tumor cells manage their energy production strategy: When oxygen concentration is below a specific threshold, they change their energy metabolism from aerobic to anaerobic.

During the simulation, at each time step, each simulated cell should decide what its biochemical state is. The cell should decide on many dimensions; such as whether it will die or not, how it will produce energy, its substance consumption budget. Moreover, whether if any mutations will occur. This should be completed before other decisions are given, since nearly all other subsystems are effected by genetic variations.

After genetic changes occur, the cell starts to explore its environment to find if there is any other cells in the neighborhood and detect amount of vital substances to use them in decision making process. Then the cell decides, how it will produce energy, by using aerobic or anaerobic energy metabolisms. Finally the cell decides for its phenotype between, apoptosis, quiescence, proliferative or migrative states. Decision process is based on probabilistic functions formed by us. Weights of the variables are found using optimization which are explained in results section. Details of functions used in subsystems are explained in the following subsections. Overview of the model can be seen in Figure 13

5.1 Proliferation

Each simulated cell's proliferation subsystem decides whether the cell is in a proliferating state or not. When the cell is *quiescent*, if there is free space for growth, if parameters such as nutrition and oxygen level are favorable, then cell has a good chance of proliferating.

It is assumed that the maximum rate of proliferation will take place at optimal conditions. When cell's microenvironment is closer to optimal conditions the proliferation probability increases; otherwise it decreases. Inputs used for the proliferation decision are oxygen concentration, glucose concentration and pH. Genetic

effects are also used in the probability distribution function. The equation 3 is used to decide the proliferation state of the cell:

$$P_r(P_g, P_h, P_d) = \begin{cases} w_{po} \times p_o + w_{pg} \times p_g + w_{ph} \times p_h + p_d, & \text{if Cell's Metabolism is Aerobic} \\ w_{pg} \times p_g + w_h \times w_{ph} + p_d, & \text{if Cell's Metabolism is Anaerobic} \end{cases} \quad (3)$$

In equation 3, P_r represents the weighted proliferation probability, P_o is the probability coefficient for oxygen. P_o is calculated based on oxygen concentration at the coordinates of cell which represented with m_o and given by:

$$P_o = \frac{m_o - ho_a}{c_o - ho_a} \quad (4)$$

In equation 4, ho_a is hypoxia induced apoptosis threshold which is the minimum oxygen concentration for proliferation and c_o is background oxygen concentration which is the maximum oxygen concentration for cell's microenvironment as given

in Table 1. Probability coefficient for glucose P_g , represents glucose concentration at the coordinates of the cell:

$$P_g = \frac{m_g - hg_a}{c_g - hg_a} \quad (5)$$

Calculation of the probability coefficient for pH, represented by P_h , is more complex than P_o and P_g , because for oxygen and glucose higher concentration correlates with higher probability for proliferation, but for pH, the cell needs an optimal pH level to have the highest chance of proliferation. Thus, P_h is calculated as a piecewise function:

$$P_h = \begin{cases} \frac{m_{ph} - \min_{ph}}{ph_o - \min_{ph}}, & \text{if } m_{ph} < ph_o \\ \frac{|m_g - \max_{ph}|}{|ph_o - \max_{ph}|}, & \text{if } m_{ph} > ph_o \\ 1, & \text{if } m_g = ph_o \end{cases} \quad (6)$$

where $\min_{ph}$, $\max_{ph}$ are minimum and maximum values of pH that a tumor cell can live under; ph_o is the optimal pH level for proliferation as given in table 1 and m_{ph} is pH level at the coordinates of cell.

Finally, P_d represents effects of the cell's accumulation of mutations on the proliferation probability and will be explained in subsection 5.8.

5.2 Invasion

When a cell decides on proliferation or migration, the next question is about finding the most convenient place to do so. The *invasion system* models this decision based on microenvironment conditions. The invasion system uses oxygen, glucose and H+ concentration as input parameters. When scanning neighbour cells with traditional methods for invasion, a strange effect occurs, as mentioned by Gerlee and Anderson [49]. The tumor tends to grow in a tree-like way, sprouting branches. Although we could not explain this effect, we overcome this issue by scanning cells orthogonally and diagonally at consecutive time steps, in interleaved fashion, as explained in Gerlee and Anderson.

To find optimal invasion coordinates, the cell prefers the direction where oxygen and glucose concentration is maximum. For H+ concentration the cell should look for optimal pH level or nearest level to optimal, given as ph_o in table 1. The invasion propensity score s_{inv} can then be calculated as:

$$s_{inv} = \begin{cases} w_{mo} \times m_o + w_{mg} \times m_g + w_{mh} \times m_h, & \text{if Cell's Metabolism is Aerobic} \\ w_{mg} \times m_g + w_{mh} \times m_h, & \text{if Cell's Metabolism is Anaerobic} \end{cases} \quad (7)$$

An error margin (e_{inv}) should be determined which simulates the transient insensitivity of cells to proliferative opportunities. When maximum s_{inv} is determined, each cell's s_{inv} is compared to the maximum s_{inv} . If the difference between them

is not more than e_{inv} then this cell is a candidate for invasion. After all candidates are determined, one candidate is selected randomly and a new tumor cell appears at coordinates of the chosen cell.

5.3 Migration

Cell migration is an important factor in the morphology of the tumor. Tumor cells may decide to migrate if conditions are not suitable to survive or proliferate. In the migration subsystem of our model, each simulated tumor cell decides whether to manifest a migrative phenotype or not. Then, it finds a suitable place for invasion by using invasion subsystem and finally it invades the location directly or by using the cell movement subsystem. The migration subsystem decides to manifest the most likely phenotype with a naive Bayes approach similar to the proliferation subsystem. There are three types of environmental parameters that force a cell to migrate. The first one is the oxygen level. When oxygen level decreases below ho_a then the cell's possibility of choosing a migrative phenotype is calculated with equation 8

$$P_{hom} = \frac{ho_m - m_o}{ho_m} * 100 \quad (8)$$

where P_{hom} stands for hypoxia based migration probability in percent, ho_m is hypoxia induced migration threshold which is determined based on simulation results as $5 \times ho_{gl}$ (see table 1) and m_o is oxygen concentration at the cell's coordinates. In a similar way migration probability based on glucose level can be calculated with 9:

$$P_{hgm} = \frac{hg_m - m_g}{hg_m} * 100 \quad (9)$$

where P_{hgm} stands for hypoglycemia based migration probability in percent, hg_m is hypoglycemia induced migration threshold which is determined based on simulation results as $5 \times hg_a$ (see table 1) and m_g is glucose concentration at the cell's coordinates.

5.4 Apoptosis

Beyond natural apoptosis, three cases are considered for apoptosis in our model: Hypoxia, hypoglycemia and extremely low pH level can cause apoptosis.

When the oxygen level decreases below %1.5, hypoxia starts until oxygen runs out (%0). It has been shown that %55 of NSCLC Adenocarcinoma (A549) cells die when oxygen level reaches %0. Also, it is known that natural apoptosis rate is %10 for A549 cells [57].

Since $\frac{55-10}{1.5-0} = 3$ for each %0.1 change at oxygen level, apoptosis survival probability increases %3. Based on this assumption, hypoxia based apoptosis probability can be calculated as:

$$P_{ha}(M_o, P_{da}) = \frac{\frac{(1.5-m_{po})}{0.1} \times 3 + 10}{100} - p_{da} \quad (10)$$

where oxygen concentration at the coordinates of the cell are represented with m_{po} and probability of as genetic effects decreases apoptosis chance and is represented by p_{da} .

Cells can live without oxygen but not without glucose. Hypoglycemia induced apoptosis probability (P_{ha}) can be calculated when $m_g < hg_a$ as follows:

$$P_{ha}(M_g, P_{da}) = \frac{m_g}{hg_a} - p_{da} \quad (11)$$

The last factor which causes apoptosis is pH level. An acidic microenvironment is favorable for the tumor because cancerous cells are more resistant to acidic environment than parenchyma. But, when pH level decreases to severely low levels all kinds of cells starts to die. When this effect is modeled, pH level at the coordinates of the cell is represented by m_h and min_{ph} stands for the minimum pH level of cell microenvironment. Thus, we can calculate P_{ha} (apoptosis probability based on pH) as:

$$P_{ha}(M_h, P_{da}) = \frac{m_h - min_{ph}}{ph_a - min_{ph}} - p_{da} \quad (12)$$

Apoptosis probability is calculated using oxygen, glucose and pH level. However, even as the cell decides to start apoptosis it will wait for a period. This delay act as a low-pass filter and prevents the cell from being affected by noise and momentary oscillations of microenvironment signals. There are more complicated methods that can be found in literature to model delayed systems [66].

5.5 Energy Metabolism

Tumor cells can produce energy by using two different metabolisms; aerobic and anaerobic. In aerobic metabolism, oxygen and glucose are used to produce energy:

In the anaerobic metabolism, only glucose is used to produce energy:

In our model, the energy metabolism shift is only based on oxygen concentration; genetic effects are ignored for the sake of simplicity.

Metabolism shift starts at %5 oxygen concentration with %20 probability and reaches %100 probability at %1 oxygen concentration [57]. If the concentration is over %5 then cell always chooses aerobic metabolism. Oxygen concentration at coordinates of cell as percentage (m_{po}) is obtained from:

$$m_{po} = m_o / C_0 \quad (15)$$

and the probability of a cell's metabolism change from aerobic to anaerobic is calculated by:

$$P_e = \begin{cases} \frac{m_{po}^{-1}}{100}, & \text{if } 0.01 \leq m_{po} \leq 0.05 \\ 1, & \text{if } m_{po} < 0.01 \end{cases} \quad (16)$$

There is also a delay introduced before the decision for a metabolism shift, with the same rationale as for the delay for the apoptosis decision, explained above.

5.6 Oxygen - Glucose Consumption and Acid Production

Tumor cells have a baseline oxygen consumption rate, represented by u_o as seen in Table 1, but this rate changes based on cellular conditions. For example a cell will not use oxygen when under anaerobic metabolism. Also, the cell's state will effect oxygen consumption. We assume that the cell consumes %50 more oxygen in proliferative state than in the quiescent state.

Glucose consumption (u_g) is a calculated in a similar way. Glucose consumption in aerobic and anaerobic states are calculated based on the stoichiometry of the respective metabolisms. Proliferative cells are assumed to use %50 more glucose, similar to oxygen.

Acid production is observed in the anaerobic metabolism, due to glycolysis. Hydronium production rate (p_h) is taken from literature [49]. At proliferative state, hydronium production is assumed to increase by %50, since glucose consumption increases with same ratio.

5.7 Cell Stress and Movement

Physical simulations on tumors shows us that there is a proliferative belt on tumor mass. This belt is caused due to various reasons, e.g. cell-cell adhesion and cell-ECM adhesion [4]. In our model, instead of treating each physical effect one by one in detail, we use a *stress score* variable.

The stress score for each cell is calculated proportional to the cell's distance from tumor's edge. Pressure on cells located in deeper parts of tumor will be higher than cells which are located at the edge of the tumor because of cell-cell adhesion and cell-ECM adhesion. Edge cells' tendency of migration is thus higher than deep cells.

5.8 Genetic Effects on Tumor

When modeling cancer, simulating genetic effects, taking in to account all variations is intractable. Since the aim of this study is only creating a simple proof of concept model, just a few important mutations of A549 are included, based on literature [44].

Our model uses an inheritance mechanism. When a simulated cell proliferates, it copies the DNA of its ancestor, so mutations are transferred between generations. As a first step, relationship between mutations determined. After this step, probabilities of mutations calculated. Finally, effects of the mutations are added to the model. In the model, only two types of mutation effects are considered: mutations' effects on probabilities of proliferation and apoptosis.

For both, if any mutation occurs in a cell, each driver mutation provides only a small selective growth advantage to the cell, on the order of a 0.4% increase in the difference between cell birth and cell death [67]. Since only 5%-10% of these are driver mutations, we calculate each driver will have an effect of 8%. Thus, if any mutation occurs in a cell, it is assumed that proliferation probability increases 8% or apoptosis probability decreases 8% based on mutation type. These relationships and effects are shown in Table 2 with minimum and maximum probabilities of observing said mutations in the population.

Table 2 Mutations of A549 Used In Model

Mutation	Minimum Probability	Maximum Probability	Ancestors	Effect Type
EGFR [68]	10	35	None	Proliferation
KRAS [69]	33	-	None	Proliferation
NTRK3 [70]	3	-	None	Proliferation
TP53 [70]	30	50	KRAS	Apoptosis
ATM [70]	10	20	KRAS	Proliferation
STK11 [70]	18	-	TP53, NTRK3	Apoptosis
CDK2NA [70]	5	-	TP53	Apoptosis

The model for the mutations is based on a Bayesian network. At each time step, a simulated cell triggers its own mutation system. For each mutation, preconditions are checked. For example for A549, EGFR mutation almost never occurs in tumors with KRAS mutation or TP53 mutation occurs if KRAS gene has a mutation. For the sake of the simplicity we assume that these mutations are all pathogenic.

After ancestors of the mutation are validated, a mutation probability is determined for each viable mutation. Finally, if a mutation occurs, effects of said mutations, whether on proliferation or apoptosis, are applied to the cell in question, and will affect its future decision equations.

6 Conclusion and Future Work

Literature includes many studies on personalized medicine, but most of these are results of bulk biostatistics and bioinformatics analyses. Tumor models on the other hand, have potential in providing mechanistic and simulated personalized predictions. In this study, we demonstrate a tumor model based on empirical observations and biochemical properties from previous literature that is amenable to tuning and extension, and able to provide personalized predictions.

To the best of our knowledge, our model is the first one that can predict personalized growth patterns of lung adenocarcinoma and validate it with xenograft model data. A hierarchical Bayesian network modeling the genotypes of tumor subpopulations was also created to predict ordering and timing of mutations during tumor progression.

We validated our model's behavior with experimental data from literature. We observed that both under hypoxia and hypoglycemia our model's growth pattern is in line with experimental results. Furthermore, our model shows the expected Gompertzian curve in chemotactic behaviour and in general growth pattern. Our personalization strategy is also promising. We have shown that if a model consistent with tumor biology can be developed, it can be personalized using a simple parameter optimization method like simulated annealing.

In the future we will extend our model by simulating effects of the immune system and integrate chemotherapy, radiotherapy and immunotherapy results to our model towards developing a clinical decision support tool.

Appendix A

$m(\vec{c}, t)$ means concentration of substance at coordinates $\vec{c}$ at time t . D is diffusion constant of substance. Since our model is 2D,

$$\vec{c} = (x, y) \quad (17)$$

we could know concentration of substance at specified coordinates at time t . To solve equation it could also be written as below:

$$\frac{\partial m(\vec{c}, t)}{\partial t} = D \left(\frac{\partial^2 m}{\partial x^2} + \frac{\partial^2 m}{\partial y^2} \right) \quad (18)$$

A detailed explanation for this equation could be found in literature [71]. Physical representation of diffusion phenomenon which is represented as equation 18 could be seen in figure:

After the basic equation of diffusion is formed, only a source term is needed which represents consumption or production of the substance for a coordinate at a specific time [71]:

$$s(\vec{c}, t) = s(x, y, t) \quad (19)$$

Oxygen and glucose which are consumed by cells are subtracted from equation 18:

$$\frac{\partial m(\vec{c}, t)}{\partial t} = D \left(\frac{\partial^2 m}{\partial x^2} + \frac{\partial^2 m}{\partial y^2} \right) - s(\vec{c}, t) \quad (20)$$

and source term for hydrogen ions (H⁺) which are produced at the end of glycolysis is added:

$$\frac{\partial m(\vec{c}, t)}{\partial t} = D \left(\frac{\partial^2 m}{\partial x^2} + \frac{\partial^2 m}{\partial y^2} \right) + s(\vec{c}, t) \quad (21)$$

Now effects of capillaries should be added to equation. We accomplish this by using a implicit source term which is a product of a fixed value with diffusion term (m). We also multiply it with a huge value (H) to winnow effects of neighbors out. We write the final equation for consumed substances as:

$$\frac{\partial m}{\partial t} = D \nabla^2 m + m H s_{cap} - s_{cell} \quad (22)$$

for produced substances it will be:

$$\frac{\partial m}{\partial t} = D \nabla^2 m - m H s_{cap} + s_{cell} \quad (23)$$

Finally, initial and boundary conditions for equations 20 - 21 will be determined [72]. We assume that boundaries of grid with $L \times L$ size, concentration equals to 0. Initial conditions could be defined as

$$\begin{aligned} m(x, y, 0) &= f(x, y), \quad \forall (x, y) \in R, \\ R &= [0, L] \times [0, L] \end{aligned} \quad (24)$$

with Dirichlet boundary conditions

$$\begin{aligned} m(x, 0, t) &= m(x, L, t) = 0, \quad 0 \leq x \leq L, \quad \forall t \geq 0 \\ m(0, y, t) &= m(L, y, t) = 0, \quad 0 \leq y \leq L, \quad \forall t \geq 0 \end{aligned} \quad (25)$$

6.1 Non-dimensionalization

Non-dimensionalization can be done with dividing each term of an homogeneous equation to parameters which have same units [73]. In this study, diffusion constants and consumption/production rates were non-dimensionalized with the following equations:

$$d^* = \frac{3600 \times \delta_t \times d}{a} \quad (26)$$

$$r^* = \frac{3600 \times \delta_t \times r \times n}{c_b} \quad (27)$$

These are generalized form of non-dimensionalization equations. In equation 26, d^* is non-dimensional diffusion constant. Tumor cell doubling time (δ_t) multiplied by 3600 to convert hour to second. Original diffusion constant is represented with d . Area (a) is total area (in cm^2) of the grid. In equation 27, r^* represents non-dimensional consumption/production rate. Original rate is represented by r . Maximum number of tumor cells (which equals to number of grid's cells) is represented by n . Finally background concentrations are represented by c_b . Using these equations 26 - 27, $u_o, u_{ga}, u_{gan}, p_h, d_o, d_g, d_h$ were non-dimensionalized.

Competing interests

The authors declare that they have no competing interests.

Code Availability

Source code is available at: <https://gitlab.com/serbulentu/MultiscaleTumorModel>

Author details

¹Karadeniz Technical University, Universite Mah., Trabzon, Turkey. ²Cancer Systems Biology Laboratory (KanSiL), Middle East Technical University, Dumlupinar Bulvarı, No:1, 06800 Ankara, Turkey. ³Dept. of Health Informatics, Graduate School of Informatics, Middle East Technical University, Dumlupinar Bulvarı, No:1, 06800 Ankara, Turkey.

References

1. Ward, J.P., King, J.R.: Mathematical modelling of avascular-tumour growth. *IMA J Math Appl Med Biol* **14**(1), 39–69 (1997)
2. Sherratt, J.A., Chaplain, M.A.: A new mathematical model for avascular tumour growth. *Journal of Mathematical Biology* **43**(4), 291–312 (2001)
3. Araujo, R., McElwain, D.: A history of the study of solid tumour growth: the contribution of mathematical modelling. *Bulletin of mathematical biology* **66**(5), 1039–1091 (2004)
4. Macklin, P., McDougall, S., Anderson, A.R., Chaplain, M.A., Cristini, V., Lowengrub, J.: Multiscale modelling and nonlinear simulation of vascular tumour growth. *Journal of mathematical biology* **58**(4-5), 765–798 (2009)
5. Itik, M., Banks, S.P.: Chaos in a three-dimensional cancer model. *International Journal of Bifurcation and Chaos* **20**(01), 71–79 (2010)
6. Golneshan, A.A., Nemati, H.: Continuum Based Tumor Growth Modeling. *Journal of Emerging Trends in Engineering and Applied Sciences* **2**, 546–550 (2011)
7. Mansury, Y., Kimura, M., Lobo, J., Deisboeck, T.S.: Emerging patterns in tumor systems: simulating the dynamics of multicellular clusters with an agent-based spatial agglomeration model. *Journal of Theoretical Biology* **219**(3), 343–370 (2002)
8. Turner, S., Sherratt, J.A.: Intercellular adhesion and cancer invasion: a discrete simulation using the extended Potts model. *Journal of Theoretical Biology* **216**(1), 85–100 (2002)
9. Alarcón, T., Byrne, H.M., Maini, P.K.: A cellular automaton model for tumour growth in inhomogeneous environment. *Journal of Theoretical Biology* **225**(2), 257–274 (2003)
10. Zhang, L., Athale, C.A., Deisboeck, T.S.: Development of a three-dimensional multiscale agent-based tumor model: simulating gene-protein interaction profiles, cell phenotypes and multicellular patterns in brain cancer. *Journal of theoretical biology* **244**(1), 96–107 (2007)
11. Sander, L.M., Deisboeck, T.S.: Growth patterns of microscopic brain tumors. *Physical Review E* **66**(5), 051901 (2002)
12. Anderson, A.R.: A hybrid mathematical model of solid tumour invasion: the importance of cell adhesion. *Mathematical Medicine and Biology* **22**(2), 163–186 (2005)
13. Giard, D.J., Aaronson, S.A., Todaro, G.J., Arnstein, P., Kersey, J.H., Dosik, H., Parks, W.P.: In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. *Journal of the National Cancer Institute* **51**(5), 1417–1423 (1973)
14. Milane, L., Duan, Z., Amiji, M.: Role of hypoxia and glycolysis in the development of multi-drug resistance in human tumor cells and the establishment of an orthotopic multi-drug resistant tumor model in nude mice using hypoxic pre-conditioning. *Cancer cell international* **11**(1), 1 (2011)
15. Bates, M.K.: Culturing cells under hypoxic conditions for biologically relevant results. *American laboratory* (2012)
16. Terraneo, L., Bianciardi, P., Caretti, A., Ronchi, R., Samaja, M.: Chronic systemic hypoxia promotes Incap prostate cancer growth in vivo. *The Prostate* **70**(11), 1243–1254 (2010)
17. Danza, G., Di Serio, C., Rosati, F., Lonetto, G., Sturli, N., Kacer, D., Pennella, A., Ventimiglia, G., Barucci, R., Piscazzi, A., *et al.*: Notch signaling modulates hypoxia-induced neuroendocrine differentiation of human prostate cancer cells. *Molecular Cancer Research* **10**(2), 230–238 (2012)
18. McKeown, S.: Defining normoxia, physoxia and hypoxia in tumours—implications for treatment response. *The British journal of radiology* **87**(1035), 20130676 (2014)
19. Kagiya, G., Ogawa, R., Hyodo, F., Yamashita, K., Nakamura, M., Ishii, A., Sejimo, Y., Tominaga, S., Murata, M., Tanaka, Y., *et al.*: Development of a real-time imaging system for hypoxic cell apoptosis. *Molecular therapy. Methods & clinical development* **5**, 16009 (2016)
20. Brat, D.J., Castellano-Sanchez, A.A., Hunter, S.B., Pecot, M., Cohen, C., Hammond, E.H., Devi, S.N., Kaur, B., Van Meir, E.G.: Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. *Cancer research* **64**(3), 920–927 (2004)
21. Parra-Bonilla, G., Alvarez, D.F., Al-Mehdi, A.-B., Alexeyev, M., Stevens, T.: Critical role for lactate dehydrogenase a in aerobic glycolysis that sustains pulmonary microvascular endothelial cell proliferation. *American Journal of Physiology - Lung Cellular and Molecular Physiology* **299**(4), 513–522 (2010). doi:[10.1152/ajplung.00274.2009](https://doi.org/10.1152/ajplung.00274.2009). <http://ajplung.physiology.org/content/299/4/L513.full.pdf>
22. Birsoy, K., Possemato, R., Lorbear, F.K., Bayraktar, E.C., Thiru, P., Yucel, B., Wang, T., Chen, W.W., Clish, C.B., Sabatini, D.M.: Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides. *Nature* **508**(7494), 108–112 (2014)
23. Li, Y., Zhang, Q., Tian, R., Wang, Q., Zhao, J.J., Iglehart, J.D., Wang, Z.C., Richardson, A.L.: Lysosomal transmembrane protein laptm4b promotes autophagy and tolerance to metabolic stress in cancer cells. *Cancer Research* **71**(24), 7481–7489 (2011). doi:[10.1158/0008-5472.CAN-11-0940](https://doi.org/10.1158/0008-5472.CAN-11-0940). <http://cancerres.aacrjournals.org/content/71/24/7481.full.pdf>
24. Otto, A.M., Hintermair, J., Janzon, C.: NADH-linked metabolic plasticity of mcf-7 breast cancer cells surviving in a nutrient-deprived microenvironment. *Journal of cellular biochemistry* **116**(5), 822–835 (2015)
25. Ho, V.W., Leung, K., Hsu, A., Luk, B., Lai, J., Shen, S.Y., Minchinton, A.I., Waterhouse, D., Bally, M.B., Lin, W., Nelson, B.H., Sly, L.M., Krystal, G.: A low carbohydrate, high protein diet slows tumor growth and prevents cancer initiation. *Cancer Research* **71**(13), 4484–4493 (2011). doi:[10.1158/0008-5472.CAN-10-3973](https://doi.org/10.1158/0008-5472.CAN-10-3973). <http://cancerres.aacrjournals.org/content/71/13/4484.full.pdf>
26. Roussos, E.T., Condeelis, J.S., Patsialou, A.: Chemotaxis in cancer. *Nature Reviews Cancer* **11**(8), 573–587 (2011)
27. Mosadegh, B., Lockett, M.R., Minn, K.T., Simon, K.A., Gilbert, K., Hillier, S., Newsome, D., Li, H., Hall, A.B., Boucher, D.M., *et al.*: A paper-based invasion assay: Assessing chemotaxis of cancer cells in gradients of oxygen. *Biomaterials* **52**, 262–271 (2015)
28. Hughes-Alford, S.K., Lauffenburger, D.A.: Quantitative analysis of gradient sensing: towards building predictive

- models of chemotaxis in cancer. *Current opinion in cell biology* **24**(2), 284–291 (2012)
29. Campbell, M., Allen, W.E., Sawyer, C., Vanhaesebroeck, B., Trimble, E.R.: Glucose-potentiated chemotaxis in human vascular smooth muscle is dependent on cross-talk between the pi3k and mapk signaling pathways. *Circulation research* **95**(4), 380–388 (2004)
 30. Norton, L.: A gompertzian model of human breast cancer growth. *Cancer research* **48**(24 Part 1), 7067–7071 (1988)
 31. Bajzer, Z., Carr, T., Dingli, D., Josic, K.: Optimization of tumor virotherapy with recombinant measles viruses (2007)
 32. Dingli, D., Pacheco, J.M., Dispenzieri, A., Hayman, S.R., Kumar, S.K., Lacy, M.Q., Gastineau, D.A., Gertz, M.A.: In vivo and in silico studies on single versus multiple transplants for multiple myeloma. *Cancer science* **98**(5), 734–739 (2007)
 33. Morvan, D., Demidem, A., Papon, J., De Latour, M., Madelmont, J.C.: Melanoma tumors acquire a new phospholipid metabolism phenotype under cystemustine as revealed by high-resolution magic angle spinning proton nuclear magnetic resonance spectroscopy of intact tumor samples. *Cancer research* **62**(6), 1890–1897 (2002)
 34. Zhou, J., Hualong, Q., Zhou, P., Guo, F.: Different maspin functions in the lung adenocarcinoma a549 and spc-a1 cell lines. *International journal of molecular medicine* **36**(5), 1440–1448 (2015)
 35. Esandi, M., Van Someren, G., Vincent, A., Van Bekkum, D., Valerio, D., Bout, A., Noteboom, J.: Gene therapy of experimental malignant mesothelioma using adenovirus vectors encoding the hsvtk gene. *Gene therapy* **4**(4), 280–287 (1997)
 36. Rohatgi, A.: WebPlotDigitizer. Version: 4.1. <https://automeris.io/WebPlotDigitizer>
 37. Folkman, J., Hochberg, M.: Self-regulation of growth in three dimensions. *Journal of Experimental Medicine* **138**(4), 745–753 (1973)
 38. Eissing, T., Kuepfer, L., Becker, C., Block, M., Coboecken, K., Gaub, T., Goerlitz, L., Jaeger, J., Loosen, R., Ludewig, B., Meyer, M., Niederaalt, C., Sevestre, M., Siegmund, H.-U., Solodenko, J., Thelen, K., Telle, U., Weiss, W., Wendl, T., Willmann, S., Lippert, J.: A computational systems biology software platform for multiscale modeling and simulation: Integrating whole-body physiology, disease biology, and molecular reaction networks. *Frontiers in Physiology* **2**, 4 (2011). doi:[10.3389/fphys.2011.00004](https://doi.org/10.3389/fphys.2011.00004)
 39. Jackson, P.R., Juliano, J., Hawkins-Daarud, A., Rockne, R.C., Swanson, K.R.: Patient-specific mathematical neuro-oncology: Using a simple proliferation and invasion tumor model to inform clinical practice. *Bulletin of Mathematical Biology* **77**(5), 846–856 (2015). doi:[10.1007/s11538-015-0067-7](https://doi.org/10.1007/s11538-015-0067-7)
 40. Liu, L.L., Li, F., Pao, W., Michor, F.: Dose-dependent mutation rates determine optimum erlotinib dosing strategies for egfr mutant non-small cell lung cancer patients. *PLOS ONE* **10**(11), 1–17 (2015). doi:[10.1371/journal.pone.0141665](https://doi.org/10.1371/journal.pone.0141665)
 41. Bearer, E.L., Lowengrub, J.S., Frieboes, H.B., Chuang, Y.-L., Jin, F., Wise, S.M., Ferrari, M., Agus, D.B., Cristini, V.: Multiparameter computational modeling of tumor invasion. *Cancer Research* **69**(10), 4493–4501 (2009). doi:[10.1158/0008-5472.CAN-08-3834](https://doi.org/10.1158/0008-5472.CAN-08-3834). <http://cancerres.aacrjournals.org/content/69/10/4493.full.pdf>
 42. Anderson, A.R.A., Weaver, A.M., Cummings, P.T., Quaranta, V.: Tumor morphology and phenotypic evolution driven by selective pressure from the microenvironment. *Cell* **127**(5), 905–915 (2006). doi:[10.1016/j.cell.2006.09.042](https://doi.org/10.1016/j.cell.2006.09.042)
 43. Sottoriva, A., Sloat, P.M.A., Medema, J.P., Vermeulen, L.: Exploring cancer stem cell niche directed tumor growth. *Cell Cycle* **9**(8), 1472–1479 (2010). doi:[10.4161/cc.9.8.11198](https://doi.org/10.4161/cc.9.8.11198). PMID: 20372084. <http://dx.doi.org/10.4161/cc.9.8.11198>
 44. Misra, N., Szczurek, E., Vingron, M.: Learning gene networks underlying somatic mutations in cancer. 22nd Annual Workshop on Mathematical and Statistical Aspects of Molecular Biology (2012)
 45. Prokopiou, S., Moros, E.G., Poleszczuk, J., Caudell, J., Torres-Roca, J.F., Latifi, K., Lee, J.K., Myerson, R., Harrison, L.B., Enderling, H.: A proliferation saturation index to predict radiation response and personalize radiotherapy fractionation. *Radiation Oncology* **10**(1), 159 (2015)
 46. Saribudak, A., Ganic, E., Zou, J., Gundry, S., Uyar, M.Ü.: Toward genomic based personalized mathematical models for breast cancer tumor growth. In: Bioinformatics and Bioengineering (BIBE), 2014 IEEE International Conference On, pp. 115–119 (2014). IEEE
 47. Kogan, Y., Halevi-Tobias, K., Elishmereni, M., Vuk-Pavlović, S., Agur, Z.: Reconsidering the paradigm of cancer immunotherapy by computationally aided real-time personalization. *Cancer Research* **72**(9), 2218–2227 (2012). doi:[10.1158/0008-5472.CAN-11-4166](https://doi.org/10.1158/0008-5472.CAN-11-4166). <http://cancerres.aacrjournals.org/content/72/9/2218.full.pdf>
 48. Magda, D., Lecane, P., Prescott, J., Thiemann, P., Ma, X., Dranchak, P.K., Toleno, D.M., Ramaswamy, K., Siegmund, K.D., Hacia, J.G.: mtDNA depletion confers specific gene expression profiles in human cells grown in culture and in xenograft. *BMC genomics* **9**(1), 521 (2008)
 49. Gerlee, P., Anderson, A.R.: A hybrid cellular automaton model of clonal evolution in cancer: the emergence of the glycolytic phenotype. *Journal of theoretical biology* **250**(4), 705–722 (2008)
 50. Rossum, G.: Python reference manual. Technical report, Amsterdam, The Netherlands (1995)
 51. Guyer, J.E., Wheeler, D., Warren, J.A.: FiPy: Partial Differential Equations with Python. *Computing in Science & Engineering* **11**(3), 6–15 (2009). doi:[10.1109/MCSE.2009.52](https://doi.org/10.1109/MCSE.2009.52)
 52. Behnel, S., Bradshaw, R., Citro, C., Dalcin, L., Seljebotn, D.S., Smith, K.: Cython: The best of both worlds. *Computing in Science and Engg.* **13**(2), 31–39 (2011). doi:[10.1109/MCSE.2010.118](https://doi.org/10.1109/MCSE.2010.118)
 53. Shinnars, P.: (2011). <http://pygame.org/>
 54. Higareda-Mendoza, A.E., Pardo-Galvan, M.A.: Expression of human eukaryotic initiation factor 3f oscillates with cell cycle in A549 cells and is essential for cell viability. *Cell Div* **5**, 10 (2010)
 55. Molter, T.W., McQuaide, S.C., Suchorolski, M.T., Strovast, T.J., Burgess, L.W., Meldrum, D.R., Lidstrom, M.E.: A microwell array device capable of measuring single-cell oxygen consumption rates. *Sensors and Actuators B: Chemical* **135**(2), 678–686 (2009)
 56. Wang, Z., Zhang, L., Sagotsky, J., Deisboeck, T.: Simulating non-small cell lung cancer with a multiscale agent-based model. *Theoretical Biology and Medical Modelling* **4**(1), 1–14 (2007). doi:[10.1186/1742-4682-4-50](https://doi.org/10.1186/1742-4682-4-50)

57. Schroedl, C., McClintock, D.S., Budinger, G.S., Chandel, N.S.: Hypoxic but not anoxic stabilization of hif-1 α requires mitochondrial reactive oxygen species. *American Journal of Physiology-Lung Cellular and Molecular Physiology* **283**(5), 922–931 (2002)
58. Höckel, M., Vaupel, P.: Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. *Journal of the National Cancer Institute* **93**(4), 266–276 (2001)
59. Guo, X., Wu, G., Wei, H., Deng, X., Yang, H., Ji, Y., He, Y., Guo, Z., Xie, S., Zhong, H., *et al.*: Quantification of glucose diffusion in human lung tissues by using fourier domain optical coherence tomography. *Photochemistry and Photobiology* **88**(2), 311–316 (2012)
60. Shankland, E., Livesey, J., Wiseman, R., Krohn, K.: Multinuclear nmr studies of an actively dividing artificial tumor. *Physiological research* **51**(1), 49–58 (2002)
61. Freyer, J.P., Sutherland, R.M.: Regulation of growth saturation and development of necrosis in emt6/ro multicellular spheroids by the glucose and oxygen supply. *Cancer research* **46**(7), 3504–3512 (1986)
62. Al-Baldawi, N.F., Abercrombie, R.: Cytoplasmic hydrogen ion diffusion coefficient. *Biophysical journal* **61**(6), 1470–1479 (1992)
63. Wood, S.C., Schaefer, K.E.: Regulation of intracellular ph in lungs and other tissues during hypercapnia. *Journal of Applied Physiology* **45**(1), 115–118 (1978)
64. Williams, A., Collard, T., Paraskeva, C.: An acidic environment leads to p53 dependent induction of apoptosis in human adenoma and carcinoma cell lines: Implications for clonal selection during colorectal carcinogenesis. *Oncogene* **18**(21), 3199–3204 (1999)
65. Zhang, X., Lin, Y., Gillies, R.J.: Tumor ph and its measurement. *Journal of Nuclear Medicine* **51**(8), 1167–1170 (2010)
66. Kahraman, M.: Modelling functional dynamical systems by piecewise linear systems with delay. Master's thesis, Scientific Computing, Institute of Applied Mathematics, Middle East Technical University (2007)
67. Vogelstein, B., Papadopoulos, N., Velculescu, V.E., Zhou, S., Diaz, L.A., Kinzler, K.W.: Cancer genome landscapes. *science* **339**(6127), 1546–1558 (2013)
68. Thomas, A., Rajan, A., Lopez-Chavez, A., Wang, Y., Giaccone, G.: From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma. *Annals of oncology* **24**(3), 577–585 (2013)
69. Krypuy, M., Newnham, G.M., Thomas, D.M., Conron, M., Dobrovic, A.: High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: Kras codon 12 and 13 mutations in non-small cell lung cancer. *BMC cancer* **6**(1), 295 (2006)
70. Ding, L., Getz, G., Wheeler, D.A., Mardis, E.R., McLellan, M.D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D.M., Morgan, M.B., *et al.*: Somatic mutations affect key pathways in lung adenocarcinoma. *Nature* **455**(7216), 1069–1075 (2008)
71. Tikhomirov, V.M.: A study of the diffusion equation with increase in the amount of substance, and its application to a biological problem. In: *Selected Works of A. N. Kolmogorov. Mathematics and Its Applications (Soviet Series)*. Springer, ??? (1991)
72. Daileda, R.C.: The two didimension heat equation - Lecture Slides (2012)
73. Kirby, B.J.: *Micro and Nanoscale Fluid Mechanics*, pp. 440–449. Cambridge University Press, ??? (2010). <http://dx.doi.org/10.1017/CBO9780511760723.024>